Found: 16
Select item for more details and to access through your institution.
Comparative effectiveness clinical trials to advance treatment of myasthenia gravis.
- Published in:
- Annals of the New York Academy of Sciences, 2018, v. 1413, n. 1, p. 69, doi. 10.1111/nyas.13582
- By:
- Publication type:
- Article
First‐in‐Human Studies of MW01‐6‐189WH, a Brain‐Penetrant, Antineuroinflammatory Small‐Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 2, p. 131, doi. 10.1002/cpdd.795
- By:
- Publication type:
- Article
Intravenous Ganaxolone: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Healthy Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 248, doi. 10.1002/cpdd.1365
- By:
- Publication type:
- Article
Pregnancy in MuSK‐positive myasthenia gravis: A single‐center case series.
- Published in:
- Muscle & Nerve, 2023, v. 68, n. 1, p. 85, doi. 10.1002/mus.27839
- By:
- Publication type:
- Article
The Duke Myasthenia Gravis Clinic Registry: II. Analysis of outcomes.
- Published in:
- Muscle & Nerve, 2023, v. 67, n. 4, p. 291, doi. 10.1002/mus.27794
- By:
- Publication type:
- Article
Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.
- Published in:
- Molecular Cancer, 2010, v. 9, p. 1, doi. 10.1186/1476-4598-9-23
- By:
- Publication type:
- Article
Reduced plasmablast frequency is associated with seronegative myasthenia gravis.
- Published in:
- Muscle & Nerve, 2021, v. 63, n. 4, p. 577, doi. 10.1002/mus.27140
- By:
- Publication type:
- Article
Knowledge and perceptions of the COVID‐19 pandemic among patients with myasthenia gravis.
- Published in:
- Muscle & Nerve, 2021, v. 63, n. 3, p. 357, doi. 10.1002/mus.27130
- By:
- Publication type:
- Article
The Duke myasthenia gravis clinic registry: I. Description and demographics.
- Published in:
- Muscle & Nerve, 2021, v. 63, n. 2, p. 209, doi. 10.1002/mus.27120
- By:
- Publication type:
- Article
Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Reliability of the triple-timed up-and-go test.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies.
- Published in:
- Advanced Therapeutics, 2022, v. 5, n. 6, p. 1, doi. 10.1002/adtp.202200030
- By:
- Publication type:
- Article
Clinical outcome measures following plasma exchange for MG exacerbation.
- Published in:
- Annals of Clinical & Translational Neurology, 2019, v. 6, n. 10, p. 2114, doi. 10.1002/acn3.50901
- By:
- Publication type:
- Article
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 5, p. 1314, doi. 10.1002/cpt.3391
- By:
- Publication type:
- Article
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 6, p. 770, doi. 10.1002/jcph.853
- By:
- Publication type:
- Article
Experience of Daily Life with Generalized Myasthenia Gravis: A Qualitative Investigation and Assessment of Instrument Content Validity.
- Published in:
- Neurology & Therapy, 2023, v. 12, n. 6, p. 2079, doi. 10.1007/s40120-023-00544-y
- By:
- Publication type:
- Article